These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
355 related articles for article (PubMed ID: 33374882)
1. Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review. Dagenais RVE; Su VCH; Quon BS J Clin Med; 2020 Dec; 10(1):. PubMed ID: 33374882 [TBL] [Abstract][Full Text] [Related]
2. Real world outcomes of CFTR modulator therapy in Australian adults and children. Kuek S; McCullagh A; Paul E; Armstrong D Pulm Pharmacol Ther; 2023 Oct; 82():102247. PubMed ID: 37574040 [TBL] [Abstract][Full Text] [Related]
3. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Healthcare Resource Utilization and Associated Costs Among People With Cystic Fibrosis in the US: A Retrospective Claims Analysis. Schechter MS; Sabater-Anaya N; Oster G; Weycker D; Wu H; Arteaga-Solis E; Bagal S; McGarry LJ; Van Brunt K; Geiger JM Pulm Ther; 2023 Dec; 9(4):479-498. PubMed ID: 37874528 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review. Kapouni N; Moustaki M; Douros K; Loukou I Children (Basel); 2023 Mar; 10(3):. PubMed ID: 36980112 [TBL] [Abstract][Full Text] [Related]
5. Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosis. Marshall LZ; Espinosa R; Starner CI; Gleason PP J Manag Care Spec Pharm; 2023 Jun; 29(6):599-606. PubMed ID: 37276039 [No Abstract] [Full Text] [Related]
6. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis. Southern KW; Patel S; Sinha IP; Nevitt SJ Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364 [TBL] [Abstract][Full Text] [Related]
7. Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis. Olivier M; Kavvalou A; Welsner M; Hirtz R; Straßburg S; Sutharsan S; Stehling F; Steindor M Front Pharmacol; 2023; 14():1176815. PubMed ID: 37229253 [No Abstract] [Full Text] [Related]
8. Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in an adolescent with homozygous G85E cystic fibrosis. Stekolchik E; Saul D; Chidekel A Respir Med Case Rep; 2022; 40():101775. PubMed ID: 36411821 [TBL] [Abstract][Full Text] [Related]
9. The use of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis postliver transplant: A case series. Ragan H; Autry E; Bomersback T; Hewlett J; Kormelink L; Safirstein J; Shanley L; Lubsch L Pediatr Pulmonol; 2022 Feb; 57(2):411-417. PubMed ID: 34850610 [TBL] [Abstract][Full Text] [Related]
10. Personalized medicine with drugs targeting the underlying protein defect in cystic fibrosis: is monitoring of treatment response necessary? Niedermayr K; Gasser V; Rueckes-Nilges C; Appelt D; Eder J; Fuchs T; Naehrlich L; Ellemunter H Ther Adv Chronic Dis; 2022; 13():20406223221108627. PubMed ID: 35959505 [TBL] [Abstract][Full Text] [Related]
11. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with Phe508del mutation: Evidence from randomized controlled trials. He R; Lin F; Deng Z; Yu B SAGE Open Med; 2024; 12():20503121231225874. PubMed ID: 38249954 [TBL] [Abstract][Full Text] [Related]
12. CFTR Modulators: Current Status and Evolving Knowledge. Regard L; Martin C; Da Silva J; Burgel PR Semin Respir Crit Care Med; 2023 Apr; 44(2):186-195. PubMed ID: 36535667 [TBL] [Abstract][Full Text] [Related]
13. Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor-Ivacaftor. Tümmler B Front Pharmacol; 2023; 14():1158207. PubMed ID: 37025483 [TBL] [Abstract][Full Text] [Related]
14. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One Zemanick ET; Taylor-Cousar JL; Davies J; Gibson RL; Mall MA; McKone EF; McNally P; Ramsey BW; Rayment JH; Rowe SM; Tullis E; Ahluwalia N; Chu C; Ho T; Moskowitz SM; Noel S; Tian S; Waltz D; Weinstock TG; Xuan F; Wainwright CE; McColley SA Am J Respir Crit Care Med; 2021 Jun; 203(12):1522-1532. PubMed ID: 33734030 [No Abstract] [Full Text] [Related]
15. A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation. McKone EF; DiMango EA; Sutharsan S; Barto TL; Campbell D; Ahluwalia N; Higgins M; Owen CA; Tullis E J Cyst Fibros; 2021 Mar; 20(2):234-242. PubMed ID: 33339768 [TBL] [Abstract][Full Text] [Related]
16. Mutual Effects of Single and Combined CFTR Modulators and Bacterial Infection in Cystic Fibrosis. Cigana C; Giannella R; Colavolpe A; Alcalá-Franco B; Mancini G; Colombi F; Bigogno C; Bastrup U; Bertoni G; Bragonzi A Microbiol Spectr; 2023 Feb; 11(1):e0408322. PubMed ID: 36625583 [TBL] [Abstract][Full Text] [Related]
17. Triple Therapy for Cystic Fibrosis (Elexacaftor, Tezacaftor, and Ivacaftor): Desensitization After Skin Rash. Santos AI; Pacheco J; Cemlyn-Jones J; Gamboa F Cureus; 2023 Sep; 15(9):e46228. PubMed ID: 37905296 [TBL] [Abstract][Full Text] [Related]
18. The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis. Guerra L; Favia M; Di Gioia S; Laselva O; Bisogno A; Casavola V; Colombo C; Conese M Expert Opin Drug Discov; 2020 Aug; 15(8):873-891. PubMed ID: 32290721 [TBL] [Abstract][Full Text] [Related]